Bio-Techne Corp TECH:NASDAQ

Last Price$379.65NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22

Today's Change0(0.00%)
Bid (Size)$368.68 (1)
Ask (Size)$606.28 (1)
Day Low / HighN/A - N/A
Volume128.2 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Bio-Techne Corp ( NASDAQ )

Price: $379.65
Change: +5.54 (1.48%)
Volume: 128.2 K
4:00PM ET 8/12/2022
 
 

Biomarin Pharmaceutical Inc ( NASDAQ )

Price: $95.07
Change: 0.00 (0.00%)
Volume: 910.4 K
4:00PM ET 8/12/2022
 
 

Exact Sciences Corp ( NASDAQ )

Price: $42.71
Change: +0.35 (0.83%)
Volume: 2.4 M
4:00PM ET 8/12/2022
 
 

Halozyme Therapeutics Inc ( NASDAQ )

Price: $43.14
Change: -0.22 (0.51%)
Volume: 1.1 M
4:00PM ET 8/12/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

Insider Sell: Bio-techne
4:09PM ET 8/12/2022 MT Newswires

John L Higgins, Director, on August 10, 2022, sold 2,504 shares in Bio-techne (TECH) for $948,516. Following the Form 4 filing with the SEC, Higgins has...

--Stephens Lowers Bio-Techne Corp Price Target to $480 From $500, Maintains Overweight Rating
10:59AM ET 8/05/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Bio-Techne Fiscal Q4 Adjusted Earnings, Sales Rise; CEO Chuck Kummeth to Retire in 2024
7:32AM ET 8/04/2022 MT Newswires

Bio-Techne (TECH) reported fiscal Q4 adjusted earnings Thursday of $2.05 per diluted share, up from $1.88 a year earlier. Analysts polled by Capital IQ...

-- Earnings Flash (TECH) BIO-TECHNE CORPORATION Reports Q4 Revenue $288.2M
6:36AM ET 8/04/2022 MT Newswires

...

View all Commentary and Analysis

Baron Growth Fund Q2 2022 Shareholder Letter
4:20AM ET 8/11/2022 Seeking Alpha

Baron Asset Fund Q2 2022 Shareholder Letter
9:46PM ET 8/10/2022 Seeking Alpha

Bio-Techne Corporation (TECH) CEO Chuck Kummeth on Q4 2022 Results - Earnings Call Transcript
11:59PM ET 8/06/2022 Seeking Alpha

Bio-Techne: Resiliency Comes At A Large Premium
9:22AM ET 7/29/2022 Seeking Alpha

Company Profile

Business DescriptionBio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics & Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The View company web site for more details
Address614 McKinley Place NE
Minneapolis, Minnesota 55413-2610
Phone+1.612.379.8854
Number of EmployeesN/A
Recent SEC Filing08/12/20224
President, Chief Executive Officer & DirectorCharles R. Kummeth
CFO & Principal Accounting OfficerJames T. Hippel
Chief Medical OfficerRobert Monroe
Secretary & Chief Compliance OfficerBrenda Swierenga Furlow

Company Highlights

Price Open$373.81
Previous Close$374.11
52 Week Range$318.07 - 543.85
Market Capitalization$14.9 B
Shares Outstanding39.2 M
SectorHealth Technology
IndustryBiotechnology
Current Dividend / Yield$0.32 / 0.34%
Dividend Ex-Date08/12/2022
Dividend Pay-Date08/29/2022
Dividend Yield 5 Year Average0.62%
Next Earnings Announcement11/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings69.28
Earnings per Share$4.25
Beta vs. S&P 500N/A
Revenue$714.0 M
Net Profit Margin25.27%
Return on Equity16.43%

Analyst Ratings as of 08/12/2022

Buy
6
Overweight
2
Hold
2
Underweight
1
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset